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ABSTRACT
Abstract Patients with COPD experience respiratory
symptoms, impairments of daily living and recurrent
exacerbations. The aim of integrated disease
management (IDM) is to establish a programme of
different components of care (ie, self-management,
exercise, nutrition) in which several healthcare providers
(ie, nurses, general practitioners, physiotherapists,
pulmonologists) collaborate to provide efficient and good
quality of care. The aim of this Cochrane systematic
review was to evaluate the effectiveness of IDM on
quality of life, exercise tolerance and exacerbation related
outcomes. Searches for all available evidence were
carried out in various databases. Included randomised
controlled trials (RCTs) consisted of interventions with
multidisciplinary (≥2 healthcare providers) and
multitreatment (≥2 components) IDM interventions with
duration of at least 3 months. Two reviewers
independently searched, assessed and extracted data of
all RCTs. A total of 26 RCTs were included, involving
2997 patients from 11 different countries with a follow-
up varying from 3 to 24 months. In all 68% of the
patients were men, with a mean age of 68 years and a
mean forced expiratory volume in 1 s (FEV1) predicted
value of 44.3%. Patients treated with an IDM
programme improved significantly on quality of life
scores and reported a clinically relevant improvement of
44 m on 6 min walking distance, compared to controls.
Furthermore, the number of patients with ≥1 respiratory
related hospital admission reduced from 27 to 20 per
100 patients. Duration of hospitalisation decreased
significantly by nearly 4 days.
INTRODUCTION
Patients with COPD show great variation in symp-
toms, limitations and quality of life, which often
hampers good medical care. This calls for a multi-
faceted response, including different elements of
care (eg, smoking cessation, physiotherapeutic
reactivation, self-management, optimal medication
adherence), delivered by various healthcare provi-
ders. In the last decade, the concept of integrated
disease management (IDM) was introduced to
improve quality and efficiency of care and to
reduce healthcare costs. Earlier systematic reviews
evaluating the effectiveness of IDM in patients with
COPD precluded conclusive evidence, as they pre-
sented either limited pooled data, did not take into
account differences in study design, or are currently
out of date. Therefore, the objective of this
Cochrane systematic review was to evaluate the
effectiveness of IDM COPD programmes on the
most relevant patient-reported outcomes: quality of
life, exercise tolerance and exacerbation-related
outcomes.
METHODS
Full details of the methods are reported in the ori-
ginal Cochrane publication.1 Briefly, we included
randomised controlled trials (RCTs) published
between 1990 and 2012, in which IDM was com-
pared to a control intervention. IDM programmes
had to consist of multidisciplinary (≥2 healthcare
providers) and multitreatment (≥2 components)
interventions with duration of at least 3 months
until 12 months of follow-up. Primary outcome
measures were (health-related) quality of life, exer-
cise tolerance and exacerbation related outcomes.
We identified citations using the highly sensitive
Cochrane collaboration search strategy in all pos-
sible databases. Two reviewers independently
searched, assessed and extracted relevant data of all
RCTs. Results were pooled by applying
random-effects modelling, using the mean change
from baseline to end point for each group for con-
tinuous data; and the proportion of participants
with each event for dichotomous data. We pooled
data reported at 3 months for meta-analysis, as our
predetermined inclusion criteria postulated a pro-
gramme of at least 3 months duration (to ensure
sufficient impact). If data at 3 months were unavail-
able, we analysed the data most closely measured
after this time point. We performed subgroup ana-
lyses on type of healthcare setting (primary care vs
secondary care), type of control group (usual care
vs monodisciplinary treatment) and type of domin-
ant component of the IDM programme (exercise vs
self-management studies).
RESULTS
Included studies
Our search identified 6700 titles and abstracts,
resulting in 4776 references after removal of dupli-
cates. A total of 26 studies fulfilled the inclusion
criteria, involving 2997 patients from 11 different
countries. Overall, studies were of moderate to
good quality. In all, 68% of the study participants
were men, mean age 68 years, with mean forced
expiratory volume in 1 s (FEV1) of 44% of pre-
dicted (range for study mean 28–66). The interven-
tions were conducted in all types of healthcare
settings: primary care (8 studies), secondary care
(12 studies), tertiary care (1 study) and a combin-
ation of primary and secondary care (5 studies).
The IDM programmes involved on average 3
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(range 2–7) healthcare providers and 4 (range 2–8) components
of care.
Main effects of the intervention
The main results with a follow-up of 3–12 months are sum-
marised in table 1. The St George Respiratory Questionnaire
(SGRQ) was assessed in 13 studies (n=1425). Pooled data
showed a mean difference (MD) of −3.71 in favour of IDM
(95% CI −5.83 to −1.59, p<0.001), with a considerable
amount of heterogeneity. After sensitivity analyses correcting for
differences in study quality the direction or significance of the
effect did not change. Pooled data on four studies (n=160)
using the chronic respiratory questionnaire (CRQ) demonstrated
a clinically relevant and statistically significant result on all
domains in favour of the IDM group: dyspnoea (MD 1.02;
95% CI 0.67 to 1.36, p<0.0001), fatigue (MD 0.82; 95% CI
0.46 to 1.17, p<0.0001), emotion (MD 0.61; 95% CI 0.26 to
0.95, p<0.0005) and mastery (MD 0.75; 95% CI 0.38 to 1.12,
p<0.0001). These results were homogeneous. We pooled data
of 14 studies (n=817) using the 6-min walking distance
(6MWD). Patients treated with IDM improved their 6MWD
statistically and clinically relevant by 43.86 m (95% CI 21.83 to
65.89). There was considerable heterogeneity between the
results of the studies. Sensitivity analyses correcting for studies
with inadequate allocation concealment reduced heterogeneity,
and the remaining MD was 15.15 m, which was still statistically
significant, however not clinically relevant. Pooled data from
seven studies measuring respiratory related hospital admissions
until 12 months of follow-up showed a statistically significant
difference in favour of IDM (OR 0.68; 95% CI 0.47 to 0.99,
p=0.04). On average, 20 out of 100 patients in the IDM group
were admitted for respiratory related causes, compared to 27
out of 100 patients in the control group. We have estimated
that, for 15 patients treated with an IDM programme over
3–12 months, 1 would avoid being admitted to hospital
(number needed to treat (NNT)=15 (95% CI 9 to 505)). We
pooled data from six studies (n=741) reporting on the number
of hospitalisation days. Patients treated with IDM were dis-
charged nearly 4 days earlier from the hospital compared to
controls (MD −3.78; 95% CI −5.9 to −1.7; p<0.001). We
found no statistically significant differences between groups on
number of exacerbations, mean exacerbation rates, emergency
department visits or differences in number of antibiotics or oral
steroid courses.
In subgroup analyses, we found no differences between
patients treated in primary or secondary care on quality of life
or exercise tolerance. Subgroup analyses comparing different
types of control groups showed the MDs between IDM and
Table 1 Summary of findings
Outcomes
Illustrative comparative risks* (95% CI) Relative
effect
(95% CI)
No of
Participants
(studies)
Quality of
evidence
(GRADE) Comments
Assumed risk
(control)
Corresponding risk
(disease management)
Disease specific
quality of life on the
SGRQ, total score
(follow-up:
3–12 months)
The mean change in
the SGRQ (total
score) ranged from
3.4 lower to 6.24
higher
The mean SGRQ in the
intervention groups was 3.71
lower (5.83 to 1.59 lower).
MD −3.71
(−5.83 to
−1.59)
1425 (13
studies)
High† Minimal clinically important
difference (MCID)=−4 points, lower
score means improvement
Disease specific
quality of life on the
CRQ dyspnoea domain
(follow-up:
3–12 months)
The mean change in
the CRQ (dyspnoea
domain) ranged
from 0 to 0.2 lower
The mean CRQ dyspnoea
domain in the intervention
groups was 1.02 higher
(0.67 to 1.36 higher)
MD 1.02
(0.68 to
1.36)
160 (4 studies) Moderate‡ MCID=0.5 points. Results on the
other domains of the CRQ (fatigue,
emotion, mastery) were also all
statistically and clinically relevant.
Functional exercise
capacity (6 min
walking distance
(6MWD)) (follow-up:
3–12 months)
The mean change in
the 6MWD ranged
from 38 lower to 36
higher
The mean functional exercise
capacity in the intervention
groups was 43.86 higher
(21.83 to 65.89 higher)
MD 43.86
(21.83 to
65.89)
838 (14
studies)
Moderate§ MCID=35 m. Sensitivity analysis
showed there was inconsistency in
the effect. After removing the low
quality studies, the MD was
15.15 m (95% CI 6.37 to 23.93,
p<0.001).
Respiratory related
hospital admissions
(follow-up:
3–12 months)
27 per 100
patients
20 per 100 patients (15 to
27)
OR 0.68
(0.47 to
0.99)
1470 (7
studies)
High
Number of hospital
days per patient (all
causes) (follow-up:
3–12 months)
The mean change in
hospital days ranged
from 1.6 to 11.9
higher
The mean number of hospital
days per patient in the
intervention groups was 3.78
lower (5.9 to 1.67 lower)
MD −3.78
(−5.9 to
−1.67)
741 (6 studies) High
This table is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews 20131 (see http://www.thecochranelibrary.com for information).
Disease management compared to control for patients with COPD. Patient or population = patients with COPD. Settings: 8 studies in primary care, 12 studies in secondary care, 1 study
in tertiary care, 5 studies each in primary and secondary care. Intervention: integrated disease management. Comparison: control (usual care).
GRADE Working Group grades of evidence are as follows. High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further
research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate.
*The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
†We did not downgrade due to risk of bias, as studies contributing more than 2.7% to the meta-analysis had a low risk of bias. Sensitivity analysis on high-risk studies did not change
the effect or significance of the effect.
‡We downgraded by one as there was considerable risk of bias in two studies on allocation concealment and two studies did not blind the outcome assessor.
§We downgraded by one as all included studies were of moderate to low quality. If we removed studies that scored high or unclear risk of bias on allocation concealment, the effect
decreased to 15 m.
MD, mean difference; CRQ, chronic respiratory questionnaire; SGRQ, St George Respiratory Questionnaire.
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controls were lower in studies using a monodisciplinary treat-
ment as a control group, compared to studies using ‘usual care’
as a control group. Subgroup analyses focussing on the domin-
ant component of the IDM programme showed that studies
focusing mainly on exercise training provided a statistically sig-
nificant greater improvement on exercise capacity and quality of
life compared to studies focusing on self-management
programmes.
DISCUSSION
This systematic review provides evidence for the efficacy of
IDM COPD programmes of at least 3 months duration on
quality of life and exercise tolerance until 12 months of
follow-up. Furthermore, we demonstrated a reduction in
respiratory related hospital admissions and hospital days when
applying an IDM programme (NNT=15 to avoid 1 admission).
This is of utmost importance, as hospitalisations contribute to
the highest burden and costs in patients with COPD.
The main strength of our review is the high applicability of
evidence, as we included 26 trials from all over the world,
including interventions conducted in all types of healthcare set-
tings and with inclusion of a broad COPD population.
However, one should bear in mind that applicability may
depend on the context of available healthcare resources. Several
methodological strengths minimised the risk of bias in the
review, including an a priori published protocol, including the
definition of IDM, together with a comprehensive search strat-
egy and assessment by two independent authors to identify all
possible studies.
Limitations of this review include possible bias from poor
reporting of data and a lack of publication of study protocols
hindering investigation of so-called reporting bias. To correct
for this, we contacted study authors to acquire additional data
and we examined whether the outcome measures reported in
the methods section were reported in the results section.
Furthermore, we acknowledge the fact that controls substantially
differs between countries and between healthcare settings. Our
subgroup analyses suggest that the effects on the outcome mea-
sures could be less strong if controls received one component of
IDM compared to patients receiving no treatment or usual care.
This review includes new trials that were not included in the
earlier published systematic reviews analysing IDM in patients
with COPD, and we were able to perform meta-analyses on all
outcomes. Some studies included in this review were also evalu-
ated in the Cochrane review addressing the effectiveness of pul-
monary rehabilitation2 or in the Cochrane review addressing the
effectiveness of self-management.3 Subgroup analyses in our
review demonstrated the largest effects on exercise capacity and
quality of life in studies incorporating some form of exercise
training, suggesting the necessity of including an exercise com-
ponent in an IDM programme. This is in line with the results of
those two reviews, where effects on exercise capacity and
quality of life tended to be higher and clinically relevant in the
pulmonary rehabilitation review, whereas in the self-
management review there was no effect on exercise capacity at
all and the effect on quality of life was too small to be of clinical
relevance.2 3
We advise authors of future trials to report a proper descrip-
tion of the processes of randomisation, data collection and the
details of the intervention prior to the start of the study in one
of the trial registers. Finally, we advise authors to measure at
least health-related quality of life, exercise tolerance or exacer-
bation related outcomes. We would endorse consensus on
reporting of common outcomes, such as change from baseline.
Long-term results on the effectiveness of IDM are still unclear,
as only two studies published 2-year follow-up data, which
demonstrated inconsistent results (data not shown). Therefore,
we recommend future trials to include long-term follow-up
data.
This article is based on a Cochrane Review published in the
Cochrane Database of Systematic Reviews 2013, DOI: 10.1002/
14651858.CD009437 (see http://www.thecochranelibrary.com
for information). Cochrane Reviews are regularly updated as
new evidence emerges and in response to feedback, and the
Cochrane Database of Systematic Reviews should be consulted
for the most recent version of the review.
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